Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Immunovia in connection with its rights issue of up to SEK 202 million
Mandate

Vinge is advising Immunovia in connection with its rights issue of up to SEK 202 million

February 20, 2023 Capital Markets and Public M&A

Immunovia AB (publ) is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Immunovia’s shares are listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Dain Hård Nevonen, Amanda Knutsson, Anders Sundin Lundberg and Adrian Filipovic.

Related

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Carlstedt & Lindh AB and Brahe Revisionsbyrå AB

 Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of Carlstedt & Lindh AB and Brahe Revisionsbyrå AB
April 24, 2025

Vinge advises Biotage in connection with RWK Bidco’s public tender

On 22 April 2025, RWK Bidco AB, a newly formed company indirectly wholly owned by KKR Funds, announced a public tender offer to the shareholders in Biotage AB to tender all ordinary shares in Biotage to RWK Bidco at a price of SEK 145 in cash per ordinary share.
April 22, 2025

Vinge advises Baseload Capital in connection with an investment from Google

 Vinge has advised Baseload Capital Holding AB in connection with securing an investment from Google.
April 16, 2025